EcoDrugPlus

5-Hydroxytryptamine Receptor 3e

Ensembl ID : ENSGGOG00000041086
Gene Symbol: HTR3E
2 Cross references
37 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSGGOG00000016400
Gene Symbol: HTR4
2 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSGGOG00000015522
Gene Symbol: HTR5A
2 Cross references
210 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSGGOG00000005275
Gene Symbol: HTR6
2 Cross references
114 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSGGOG00000016305
Gene Symbol: HTR7
2 Cross references
218 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

A-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSGGOG00000008695
Gene Symbol: ARAF
2 Cross references
191 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSGGOG00000010586
Gene Symbol: ABL1
2 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adam Metallopeptidase Domain 17

Ensembl ID : ENSGGOG00000013128
Gene Symbol: ADAM17
2 Cross references
282 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrm1 26s Proteasome Ubiquitin Receptor

Ensembl ID : ENSGGOG00000008457
Gene Symbol: ADRM1
2 Cross references
255 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Akt Serine/threonine Kinase 1

Ensembl ID : ENSGGOG00000012984
Gene Symbol: AKT1
2 Cross references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Akt Serine/threonine Kinase 3

Ensembl ID : ENSGGOG00000007722
Gene Symbol: AKT3
2 Cross references
201 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Atp Binding Cassette Subfamily B Member 1

Ensembl ID : ENSGGOG00000001146
Gene Symbol: ABCB1
2 Cross references
161 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).